Focus Stocks
Above Resistance: Amgen
Published on Tuesday, 03 July 2012 07:00 Written by TradersHuddle Wire
New York, July 3rd (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) closed the session at $74.36 just above calculated resistance at $73.75. The stock effectively broke out and grasped the attention of momentum traders, which could eventually push the stock to a different trading range.
Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The company concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
The stock was trading in a well defined range with support at $56.00 and resistance at $73.75. Given that this range was broken, traders will be closely monitoring Amgen's price action to gather clues on the future direction.
From a technical perspective, it can be expected that previous resistance becomes support, as the new range gets defined. However, given that Amgen is still near the broken resistance level, traders will be focusing on the $73.75 level to see if the stock holds the breakout without rolling over.
Related Articles
- Trading the Setup In Amgen
- NASDAQ 100 Round Up - Flat: FSLR, CTRP, BIDU
- Reference Points for Amgen
- How to Play the Building Momentum in Amgen
- Trading Idea: Is Amgen close to Support?
- Amgen Is Close to the 50 Day Moving Average
- Amgen Is Close to its 50 Day Moving Average
- Amgen is Near a Key Support Area
- Is Amgen Close to Support?
- Reference Points for Amgen
Related Partner Headlines
- Cramer's Top Stock Picks: AMGN, HPY, but Avoid JCP - TheStreet.com
- Amgen Stock To Go Ex-dividend Tomorrow (AMGN) - TheStreet.com
- Amgen Inc (AMGN): Today's Featured Drugs Winner - TheStreet.com
- Amgen Inc Stock Buy Recommendation Reiterated (AMGN) - TheStreet.com
- Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial Did Not Meet Primary Endpoint - Benzinga
- Amgen Inc Stock Buy Recommendation Reiterated (AMGN) - TheStreet.com
- UPDATE: Oppenheimer Raises PT to $89 on Amgen - Benzinga
- UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Amgen - Benzinga
- Amgen's Third Quarter Earnings Report - Investopedia
- Analysts' Actions: CAT AMGN DNKN BTU COF - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,294.50 Trade time:4:53PM EDT Value change:▼12.67 (-0.08%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,650.51 Trade time:4:52PM EDT Value change:▼4.84 (-0.29%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,459.42 Trade time:5:15PM EDT Value change:▼3.88 (-0.11%)In The Wires
-
Agnico Eagle Mines Limited Announces Investment in Probe Mines Limited -
Lifshitz Law Firm Announces Investigation of Mayflower Bancorp, Inc., Multiband Corporation, rue21, inc., and SoundBite Communications -
PrivateBancorp Stockholders Approve All Proposals -
Santa Cruz County Bank Declares Cash Dividend -
Acquisition of rue21, inc. by Funds Advised by the Private Equity Firm Apax Partners May Not Be in the Best Interests of rue21 Shareholders -
Viking Minerals Inc: The Company enters into final negotiations to acquire Multi-Million dollar Coal Resource on profit sharing basis. -
Crest Supplements its Proxy Statement Opposing Revised Terms for Sprint-Clearwire Merger -
Novelis and CEO Philip Martens Win Top Honors at Platts Global Metals Awards








